Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	30 people Data from 1 RCT	Positive symptoms: <20% reduction in Scale for the Assessment of Positive Symptoms (SAPS) total score with olanzapine (mean dose 23 mg/day) with quetiapine (mean dose 826.67 mg/day) Absolute results not reported	RR 0.07 95% CI 0.00 to 1.07		Not significant
Systematic review	115 people 3 RCTs in this analysis	Mean difference in average endpoint Positive and Negative Syndrome Scale (PANSS) positive subscore short term with olanzapine (2.5–20 mg/day) with quetiapine (50–800 mg/day) Absolute results not reported	Mean difference –1.05 95% CI –2.85 to +0.75		Not significant
Systematic review	483 people 3 RCTs in this analysis	Mean difference in average endpoint PANSS positive subscore medium term with olanzapine (7.5–30 mg/day) with quetiapine (200–800 mg/day) Absolute results not reported	Mean difference –2.21 95% CI –3.52 to –0.90	Moderate effect size	olanzapine
Systematic review	81 people Data from 1 RCT	Mean difference in average endpoint PANSS positive subscore long term with olanzapine (2.5–20 mg/day) with quetiapine (100–800 mg/day) Absolute results not reported	Mean difference –1.80 95% CI –3.21 to –0.39	Effect size not calculated	olanzapine
Systematic review	30 people Data from 1 RCT	Positive symptoms: percent change in SAPS total score with olanzapine (mean dose 23 mg/day) with quetiapine (mean dose 826.67 mg/day) Absolute results not reported	Mean difference –40.84% 95% CI –57.71% to –23.97%	Effect size not calculated	olanzapine
Systematic review	30 people Data from 1 RCT	Negative symptoms: <20% reduction in Scale for the Assessment of Negative Symptoms (SANS) total score with olanzapine (mean dose 23 mg/day) with quetiapine (mean dose 826.67 mg/day) Absolute results not reported	RR 0.67 95% CI 0.23 to 1.89		Not significant
Systematic review	115 people 3 RCTs in this analysis	Mean difference in average endpoint PANSS negative subscore short term with olanzapine (2.5–20 mg/day) with quetiapine (50–800 mg/day) Absolute results not reported	Mean difference –0.01 95% CI –1.73 to +1.72		Not significant
Systematic review	483 people 3 RCTs in this analysis	Mean difference in average endpoint PANSS negative subscore medium term with olanzapine (7.5–30 mg/day) with quetiapine (200–800 mg/day) Absolute results not reported	Mean difference –0.40 95% CI –1.47 to +0.67		Not significant
Systematic review	483 people Data from 1 RCT	Mean difference in average endpoint PANSS negative subscore long term with olanzapine (2.5–20 mg/day) with quetiapine (100–800 mg/day) Absolute results not reported	Mean difference –0.70 95% CI –2.13 to +0.73		Not significant
Systematic review	335 people Data from 1 RCT	Mean difference in average endpoint SANS subscore medium term with olanzapine (10–20 mg/day) with quetiapine (300–700 mg/day) Absolute results not reported	Mean difference –3.70 95% CI –7.88 to +0.48		Not significant
Systematic review	30 people Data from 1 RCT	Negative symptoms: percent change in SANS total score with olanzapine (mean dose 23 mg/day) with quetiapine (mean dose 826.67 mg/day) Absolute results not reported	RR –2.46 95% CI –36.82 to +31.90		Not significant